AlgaVac

Microalgae-based oral vaccines for aquaculture

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in November 2022, AlgaVac operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing microalgae-based oral vaccines for aquaculture. AlgaVac has established proof-of-concept collaborations with key industry players, including Virbac and Temasek Polytechnic.

Business overview

AlgaVac is an aquaculture biotechnology company specializing in the development of algae-based oral delivery platforms for vaccines and disease treatments in fish and other aquaculture species. The company leverages genetically transformed microalgae to create an algal powder that can be integrated into feed, enabling vaccine delivery through regular feeding rather than traditional injection methods. This approach aims to reduce reliance on manual vaccination, plastic consumables, and intensive handling in aquaculture. AlgaVac operates within the Health Tech & Life Sciences sector, specifically targeting Pharma & Medical Biotechnology and Drugs Discovery & Development, with a focus on the Healthcare & Life Sciences market.

Log in to access full profile

Company Intelligence Q&A

What is AlgaVac's core technology?
AlgaVac utilizes genetically transformed microalgae as a cell-based production and bio-encapsulation system to create an algal powder for oral vaccine delivery in aquaculture.
What problem does AlgaVac aim to solve in aquaculture?
AlgaVac aims to reduce the reliance on manual injectable vaccination, plastic medical consumables, and handling-intensive disease prevention methods in aquaculture by offering an oral vaccine delivery system.
When was AlgaVac founded?
AlgaVac was founded in November 2022.
What is AlgaVac's current product development stage?
AlgaVac's products are currently in the Research & Development (R&D) stage, focusing on developing microalgae-based oral vaccines for aquaculture.
Has AlgaVac established any notable collaborations?
AlgaVac has reported proof-of-concept collaborations with Virbac, Temasek Polytechnic, and Israel’s Agricultural Research Organization for oral fish vaccine and growth-promoting applications.
Log in to access full profile